1. https://www.unaids.org/sites/default/files/media_asset/JC3032_AIDS_Data_book_2021_En.pdf
2. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272.
3. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454.
4. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; :CD003255.
5. Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward-a joint position paper of the HIV Medivine Association of the Infectious Diseases Society of America and the American
College of Physicians. Clin Infect Dis 2009;48:1335
6. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303.
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.
8. Van de Perre P, Jacobs D, Sprecher-Goldberger S. The latex condom, an efficent barrier against sexual transmission of AIDS-related viruses. AIDS 1987;
Van de Perre P, Jacobs D, Sprecher-Goldberger S. The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1987; 1:49.
9. Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virüs permeability of a new condom for women. Sex Transm Dis 1990,17:110
10. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
11. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643.
12. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.
13. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012; 26:609.
14. Grabowski MK, Serwadda DM, Gray RH, et al. HIV Prevention Efforts and Incidence of HIV in Uganda. N Engl J Med 2017;377:2154
15. Auvert B, Taljaard D, Rech D, et al. Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using
cross-sectional surveys. PLoS Med 2013; 10:e1001509.
16. Kigozi G, Musoke R, Kighoma N, et al. Safety of medical male circumcision in human immunodeficiency virus-infected men in Rakai, Uganda. Urology 2014; 83:294.
17. Kong X, Kigozi G, Ssekasanvu J, et al. Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda. JAMA 2016;
316:182.
18. Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir
Immune Defic Syndr 2007; 44:66.
19. Kong X, Kigozi G, Nalugoda F, et al. Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai,
Uganda. Am J Epidemiol 2012; 176:875.
20. Millett GA, Flores SA, Marks G, et al. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008; 300:1674.
21. Scott-Sheldon LA, Huedo-Medina TB, Warren MR, et al. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010.
J Acquir Immune Defic Syndr 2011; 58:489.
22. Eaton LA, Huedo-Medina TB, Kalichman SC, et al. Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention
packages. Am J Public Health 2012; 102:e34.
23. Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; :CD004145.
24. Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) 2007; 29:35.
25. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376:268.
26. Stillwaggon E, Sawers L. Rush to judgment: the STI-treatment trials and HIV in sub-Saharan Africa. J Int AIDS Soc 2015; 18:19844.
27. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621.
28. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized
controlled trial. JAMA 2004; 291:2555.
29. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011, 378:e23-5.
30. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016, 375:830-9.
31. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J AIDS 2005, 40:96-101.
32. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of HIV type 1. N Engl J Med 2000, 342:9219.
33. Barreiro P, del Romero J, Leal M, et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J AIDS 2006;43:324-6.
34. Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive An-
tiretroviral Therapy. JAMA 2016; 316:171-181.
35. Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet 2023, S0140-6736(23)00877-2.
36. Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011
survey. AIDS 2012, 26:971-5.
37. Mujugira A, Coombs RW, Heffron R, et al. Seminal HIV-1 RNA Detection in Heterosexual African Men Initiating Antiretroviral Therapy. J Infect Dis 2016, 214:212-5.
38. https://www.cdc.gov/hiv/basics/prep/prep-effectiveness.html
39. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf
40. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
41. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
42. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.
Lancet Infect Dis. 2014;14(9):820-829.
43. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf
44. https://www.eacsociety.org/media/guidelines-12.0.pdf
45. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246.
46. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.
JAMA. 2020 Oct 27;324(16):1651-1669.
47. Mayer KH, Molina J-M, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER):
primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, noninferiority trial. The Lancet. 2020;396(10246):239-254
48. https://www.bhiva.org/file/5b729cd592060/2018-PrEP-Guidelines.pdf5-hetero
49. Irvine C, Egan KJ, Shubber Z, Van Rompay KKA, Beanland RL, Ford N. Efficacy of HIV postexposure prophylaxis: Systematic review and meta-analysis of nonhuman primate studies. Clin
Infect Dis 2015;60 Suppl 3:S165-169.
50. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention
Needlestick Surveillance Group. N Engl J Med 1997;337(21):1485-1490
51. CDC. HIV risk behaviors. 2015 Dec 4. https://www.cdc.gov/hiv/risk/estimates/riskbehaviors.html
52. DeHaan E, McGowan JP, Fine SM, et al. PEP to Prevent HIV Infection [Internet]. Baltimore (MD): Johns Hopkins University; New York State Department of Health AIDS Institute Clinical
Guidelines.2022 Aug 11.
53. Cresswell F, Asanati K, Bhagani S, et al. UK guideline for the use of HIV post-exposure prophylaxis 2021. HIV Med. 2022 May;23(5):494-545.
54. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking supp-
ressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393(10189):2428-2438.
55. Noe S. Post-exposure prophylaxiss (PEP). In: Hoffmann C, Rockstroh JK, eds. HIV 2023/2024. www.hivbook.com.
56. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency
virus type 2). J Virol 2000;74(20):9771-9775.
57. Beymer MR, Weiss RE, Bolan RK, et al. Differentiating Non occupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles,
California. Open Forum Infect Dis 2017;4(2):ofx061.
58. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne
infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72(5):4265-4273.
59. Cottrell ML, Garrett KL, Prince HMA, et al. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. J Antimicrob Chemother 2017;72(6):1731-
1740.
60. Haynes BF, Wiehe K, Alam SM, Weissman D, Saunders KO. Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development. Curr
Opin HIV AIDS 2023;18(6):300-308.
61. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent
HIV-1 infection. J. Infect. Dis 2005; 191, 654–665.
62. Pitisuttithum P, Gilbert P, Gurwith M, et al; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1
vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis 2006; 194, 1661–1671.
63. Harrer T. Preventive HIV-1 Vaccination: current status. In: Hoffmann C, Rockstroh JK, eds. HIV 2023/2024. www.hivbook.com.
64. Buchbinder SP, Mehrotra DV, Duerr A, et al; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study):a double-blind, randomised, place-
bo-controlled, test-of-concept trial. Lancet 2008;372, 1881–1893.
65. Gray GE, Allen M, Moodie Z, et al; HVTN 503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind,
randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis 2011; 11, 507–515.
66. Hammer SM, Sobieszczyk ME, Janes H, et al; HVTN 505 Study Team. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013;369, 2083–2092.
67. Gray GE, Mngadi K, Lavreys L, et al. Phase IIb efficacy trial of mosaic HIV-1 vaccine regimen in African women: Imbokodo. Conference on Retroviruses and Opportunistic Infections, abst-
ract 121, 2022.
68. Rerks-Ngarm S, Pitisuttithum P, Excler JL, et al; RV305 Study Team. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection. J Infect Dis 2017;215(8):1255-1263.
69. Bekker LG, Moodie Z, Grunenberg N, et al; HVTN 100 Protocol Team. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South Afri-
can adults: a phase 1/2 trial. Lancet HIV 2018;5(7):e366-e378.
70. Gray GE, Bekker LG, Laher F, et al; HVTN 702 Study Team. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N Engl J Med. 2021;384(12):1089-1100.
71. Corey L, Gilbert PB, Juraska M, et al; HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N
Engl J Med 2021;384(11):1003-1014.